D. Reinke

发表

B cells are associated with survival and immunotherapy response in sarcoma

J. Wargo, C. Lucchesi, A. Reyniès, 2020, Nature.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

P. Thall, J. Wathen, D. Reinke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Robin L. Jones, W. Read, H. Tawbi, 2017, The Lancet. Oncology.

Cancer- and chemotherapy-induced anemia.

M. Millenson, R. Vij, C. Cleeland, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

Robin L. Jones, S. Steinberg, D. Reinke, 2020, Sarcoma.

Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

R. Schilsky, R. Goldberg, D. Reinke, 2006 .

A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis.

J. Wathen, D. Reinke, R. Maki, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiomics-based patient inclusion model improves clinical trial performance

R. Gillies, R. Gatenby, M. Schabath, 2021, medRxiv.

Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321.

D. Reinke, R. Riedel, R. Randall, 2021, Journal of adolescent and young adult oncology.

Meaningful engagement of the patient in rare cancer research: sarcoma as an exemplar.

D. Reinke, 2021, Current problems in cancer.

Cancer- and treatment-related anemia: Clinical Practice Guidelines in Oncology

M. Millenson, G. Demetri, C. Cleeland, 2005 .

Cancer- and treatment-related anemia.

M. Millenson, G. Demetri, C. Cleeland, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results

V. Bolejack, D. Reinke, R. Maki, 2022, Cancer medicine.

Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.

S. D'Angelo, H. Tawbi, M. Burgess, 2016 .

Neo/adjuvant doxorubicin (A) and ifosfamide (I) versus gemcitabine (G) and docetaxel (T) in patients (PTS) with localized, high risk soft tissue sarcoma (STS): A randomized phase II comparative effectiveness trial.

D. Reinke, S. Schuetze, S. Wong, 2013 .

Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.

Robin L. Jones, D. Reinke, W. Tap, 2020, Journal of geriatric oncology.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

H. Tawbi, V. Bolejack, D. Reinke, 2017, Cancer.

Global Patient Involvement in Sarcoma Care—A Collaborative Initiative of the Connective Tissue Oncology Society (CTOS) & Sarcoma Patients EuroNet (SPAEN)

J. Blay, D. Reinke, R. Haas, 2022, Cancers.

Clinical trial enrollment of adolescents and young adults with sarcoma

D. Reinke, G. Schwartz, R. Randall, 2017, Cancer.

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma

B. Crompton, A. Thorner, D. Reinke, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

B cells are associated with survival and immunotherapy response in sarcoma

J. Wargo, C. Lucchesi, A. Reyniès, 2020, Nature.

SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Robin L. Jones, S. Steinberg, D. Reinke, 2017 .

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Robin L. Jones, S. Steinberg, D. Reinke, 2017, Sarcoma.

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

J. Wargo, H. Tawbi, E. Keung, 2020, Clinical Cancer Research.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

J. Crowley, I. Wistuba, H. Tawbi, 2017, The Lancet. Oncology.

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

A. Chen, D. Reinke, B. V. Van Tine, 2020, Sarcoma.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

D. Reinke, C. Meyer, L. Helman, 2019, Sarcoma.

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

Paul A Meyers, Laurence H Baker, J Kyle Wathen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

P. Thall, J. Wathen, D. Reinke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials.

D. Reinke, R. Maki, S. Schuetze, 2023, The oncologist.

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

Robin L. Jones, D. Reinke, S. Schuetze, 2021, Cancers.

Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

P. Meltzer, J. Trent, E. Kleinerman, 2014, Clinical Cancer Research.

Cancer- and chemotherapy-induced anemia.

M. Millenson, C. Cleeland, D. Cella, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

J. Wathen, D. Reinke, R. Benjamin, 2012, The oncologist.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

D. Reinke, R. Maki, B. Geoerger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study

D. Reinke, R. Maki, R. Riedel, 2018, The oncologist.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

Dafydd G. Thomas, V. Bolejack, D. Reinke, 2018, JAMA oncology.

Practical management of imatinib in gastrointestinal stromal tumors.

D. Reinke, T. Barnes, 2011, Clinical journal of oncology nursing.

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

V. Bolejack, D. Reinke, R. Maki, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Task Force Report: Oral chemotherapy.

Susan O'Brien, Saul N Weingart, Peter B Bach, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma

Dafydd G. Thomas, J. Wathen, H. Tawbi, 2016, Cancer.

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

H. Tawbi, E. Keung, M. Burgess, 2019, Journal of Clinical Oncology.

SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).

S. Steinberg, D. Reinke, S. Schuetze, 2013 .

AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance

R. Gillies, R. Gatenby, Alberto L Garcia, 2022, Tomography.

Title : Imaging-based patient inclusion model improves clinical trial performance Running title : Imaging-based model for clinical trial patient inclusion

R. Gillies, R. Gatenby, Alberto L Garcia, 2021 .

Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy: results from an observational study

P. Boonstra, D. Reinke, R. Weinberg, 2020, Journal of cancer metastasis and treatment.

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

David M. Thomas, O. Myklebost, U. Dirksen, 2016, Clinical Sarcoma Research.

NCCN Guidelines Version 3.2014 Panel Members Cancer- and Chemotherapy-Induced Anemia

M. Millenson, D. Cella, B. Djulbegovic, 2014 .

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

A. Zelenetz, Philip E. Johnson, G. Lyman, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.

D. Reinke, S. Schuetze, S. Wong, 2015, European journal of cancer.

A review of anemia management in the oncology setting: a focus on implementing standing orders.

D. Reinke, J. Mickle, 2007, Clinical journal of oncology nursing.

SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).

S. Steinberg, D. Reinke, C. Meyer, 2016 .

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

D. Reinke, K. Ballman, D. Hawkins, 2020, Cancer.

Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

J. Crowley, D. Reinke, R. Benjamin, 2010 .

A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.

J. Crowley, D. Reinke, R. Maki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.

V. Bolejack, D. Reinke, R. Maki, 2017 .

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor

Jeffrey P Leal, Hao Wang, Scott M Schuetze, 2016, The Journal of Nuclear Medicine.

SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.

H. Tawbi, M. Burgess, D. Reinke, 2015 .

Cancer Survivorship-Considering Mindsets-Reply.

D. Reinke, L. Baker, E. Antalis, 2020, JAMA oncology.

SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.

B. Brigman, M. Burgess, D. Reinke, 2018 .

Ecteinascidin-743 is a potent inhibitor of P450 3A4 enzyme and accumulates cytoplasmic PXR to inhibit transcription of P450 3A4 and MDR1: Implications for the enhancement of cytotoxicity to chemotherapeutic agents in osteosarcoma

D. Reinke, E. Mensah-Osman, L. Baker, 2005 .

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Binsheng Zhao, Scott M Schuetze, Laurence H Baker, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS).

P. Thall, J. Wathen, D. Reinke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Task Force Report: Oral chemotherapy.

D. Reinke, L. Saltz, P. Bach, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.

H. Tawbi, L. Butterfield, M. Burgess, 2017 .

Practical management of imatinib in gastrointestinal stromal tumors.

D. Reinke, T. Barnes, 2011, Clinical journal of oncology nursing.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Robin L. Jones, W. Read, H. Tawbi, 2017, The Lancet. Oncology.